Take a look at our previous reports:

Consolidated statements of income and comprehensive income/loss (-)

Consolidated income statement

 

Year ended 31 December

 

(thousands of €, except per share data)

2023

2022(*)

Notes

Collaboration revenues

239,724

241,249

7

Total net revenues

239,724

241,249

 

 

 

 

 

Research and development expenditure

(241,294)

(269,797)

8

Sales and marketing expenses

(5,676)

(3,480)

8

General and administrative expenses

(128,289)

(135,155)

8

Other operating income

47,272

36,127

8

 

 

 

 

Operating loss

(88,263)

(131,056)

 

 

 

 

 

Fair value adjustments and net currency exchange differences

16,252

51,498

10

Other financial income

80,249

18,563

10

Other financial expenses

(2,613)

(9,854)

10

 

 

 

 

Profit/loss (-) before tax

5,625

(70,849)

 

 

 

 

 

Income taxes

(9,613)

(572)

11

 

 

 

 

Net loss from continuing operations

(3,988)

(71,421)

 

 

 

 

 

Net profit/loss (-) from discontinued operations, net of tax

215,685

(146,570)

5

 

 

 

 

Net profit/loss (-)

211,697

(217,991)

 

 

 

 

 

Net profit/loss (-) attributable to:

 

Owners of the parent

211,697

(217,991)

 

Basic and diluted earnings/loss (-) per share

3.21

(3.32)

12

Basic and diluted loss per share from continuing operations

(0.06)

(1.09)

 

(*)

The 2022 comparative has been restated to reflect the impact of classifying the Jyseleca® business as discontinued operations in 2023.

The accompanying notes form an integral part of these financial statements.

Consolidated statement of comprehensive income / loss (-)

 

Year ended 31 December

 

(thousands of €)

2023

2022(*)

Notes

Net profit/loss (-)

211,697

(217,991)

 

Items that will not be reclassified subsequently to profit or loss:

 

 

 

Re-measurement of defined benefit obligation

(1,037)

5,324

 

Items that may be reclassified subsequently to profit or loss:

 

 

 

Translation differences, arisen from translating foreign activities

392

129

 

 

 

 

 

Other comprehensive income/loss (-), net of income tax

(645)

5,453

 

 

 

 

 

Total comprehensive income/loss (-) attributable to:

 

 

 

Owners of the parent

211,052

(212,538)

 

 

 

 

 

Total comprehensive income/loss (-) attributable to owners of the parent arises from:

 

 

 

Continuing operations

(4,564)

(65,953)

 

Discontinued operations

215,616

(146,586)

 

Total comprehensive income/loss (-), net of income tax

211,052

(212,538)

 

(*)

The 2022 comparative has been restated to reflect the impact of classifying the Jyseleca® business as discontinued operations in 2023.

The accompanying notes form an integral part of these financial statements.